AstraZeneca Cuts 600 U.S. Respiratory Jobs
The layoffs hit commercial staff marketing asthma drugs Breztri and Airsupra as part of a three-year cost-saving program.
Updated on Nov. 13, 2026 in Asthma

Live Poll
Do you trust large drug companies to put job cuts toward better medicine?
AstraZeneca eliminated roughly 600 positions from its U.S. respiratory and immunology commercial teams, affecting staff who market the asthma drugs Breztri and Airsupra. The company also scaled back its contract with Syneos Health, a partner that helps sell its products in the U.S. market.
Why it matters
The cuts are an early step in AstraZeneca's three-year cost-saving program and reflect a shift of resources away from mature products facing patent losses toward oncology, rare disease and next-generation pipeline work. For U.S. patients and prescribers, the changes concern how asthma medicines are marketed, though the company expects some affected employees to be reassigned internally.
The respiratory and immunology portfolio generated $7.3 billion in product revenue in the first nine months of 2026, rising 10% at constant exchange rates, with Fasenra up 13-14% and Breztri up 16-18%. How many of the roughly 600 cut roles will be reassigned versus permanently lost has not been disclosed.
The players
AstraZeneca
AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England, with more than 25,000 employees in the United States.
Syneos Health
Syneos Health is a contract research and commercialization services company that helps pharmaceutical firms sell their products in the market.
The details
AstraZeneca reportedly eliminated the positions as part of an effort to cut costs and realign its pipeline, and reportedly scaled back its contract with Syneos Health, which helps sell its products in the U.S. market. The cuts affected staff marketing Breztri and Airsupra, and some affected employees are expected to be reassigned within the company.
Timeline
First nine months of 2026: Respiratory & Immunology generated $7.3 billion in product revenue.
End of 2029: The three-year cost-saving program is expected to deliver $1.5 billion in annualized pre-tax run-rate benefits.
Pipeline Pivot
The reduction in staff marketing Breztri and Airsupra comes as AstraZeneca prepares for loss of exclusivity on Farxiga and Brilinta in certain markets and redirects resources toward its oncology and rare disease pipeline.
For people managing asthma, the restructuring concerns the commercial teams that promote Breztri and Airsupra rather than the drugs themselves, so prescriptions and availability are not described as changing. Patients should continue to follow their prescribing clinician's guidance on current inhalers.
The takeaway
Companies facing patent expirations often cut the sales and marketing support behind mature drugs while investing in new therapies, so changes in promotion do not necessarily signal changes in patient access.
Further reading
Explore more on Asthma coverage and the respiratory drugs at the center of this restructuring.
Live Poll
Do you trust large drug companies to put job cuts toward better medicine?






